Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy: Access, Regulations, and Trials Italfarmaco S.p.A. has announced significant progress in the regulatory and clinical development of givinostat, its investigational drug for…
ENCell’s EN001 Gets FDA Orphan Drug Status for Charcot-Marie-Tooth Disease ENCell, a leading biopharmaceutical company specializing in cell and gene therapy, contract research, and manufacturing, has announced that the U.S.…
Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing Elegen, a pioneer in next-generation cell-free DNA manufacturing, has announced a 25% price reduction for its…
FDA Accepts Gazyva sBLA for Lupus Nephritis Treatment Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License…
New Data Supports DNA Vaccine Delivery via Vaxxas’ HD-MAP Technology Vaxxas, a clinical-stage biotechnology company specializing in a novel vaccination platform, announced today the publication of data validating the effectiveness…
Cadrenal Therapeutics Partners with Abbott for Tecarfarin Pivotal Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company specializing in cardiovascular therapeutics, has announced the signing…
FDA Grants Orphan and Pediatric Designations to NEU-001 for Hirschsprung’s Disease Neurenati Therapeutics Inc., a biotechnology company dedicated to pediatric rare diseases, is excited to announce that the U.S. Food…
Centauri Therapeutics Selects First Clinical Candidate for Gram-Negative Infection Treatment Centauri Therapeutics Limited, an immunotherapy company leveraging its unique Alphamer® platform technology, has announced the selection of its first clinical…
Osivax Secures Funding to Advance Influenza Vaccine Development Osivax, a biopharmaceutical company focused on developing vaccines for broad-spectrum protection against rapidly mutating respiratory viruses, has announced the successful first close…
Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-0871 for CMT2C Actio Biosciences, a clinical-stage biotechnology company focused on using its “one to many” paradigm in genetics and…
SOTIO Reveals Promising Preclinical Data on SOT109 for Colorectal Cancer SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled groundbreaking preclinical data for SOT109, a novel antibody-drug…
KalVista Presents Latest Sebetralstat Findings at AAAAI 2025 KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data on sebetralstat at the 2025 American Academy of Allergy, Asthma…